Equity Overview
Price & Market Data
Price: $2.80
Daily Change: -$0.11 / 3.93%
Daily Range: $2.74 - $2.92
Market Cap: $384,423,968
Daily Volume: 375,025
Performance Metrics
1 Week: -6.40%
1 Month: 1.46%
3 Months: 57.95%
6 Months: -17.75%
1 Year: 199.9%
YTD: 91.72%
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.